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Genetic variation in the farnesoid
X‑receptor predicts Crohn’s disease
severity in female patients
Aze Wilson1,2,3*, Qian Wang4, Ahmed A. Almousa1, Laura E. Jansen1, Yun‑hee Choi5,
Ute I. Schwarz1,3 & Richard B. Kim1,3
The farnesoid X receptor (FXR) is implicated in Crohn’s disease (CD) pathogenesis. It is unclear how
genetic variation in FXR impacts CD severity versus genetic variation in nuclear receptors such as
pregnane X receptor (PXR) and the multi-drug resistance protein 1 (MDR1, ABCB1). To evaluate
FXR-1G > T as a genomic biomarker of severity in CD and propose a plausible molecular mechanism. A
retrospective study (n = 542) was conducted in a Canadian cohort of CD patients. Genotypic analysis
(FXR-1G > T, MDR1 3435C > T and PXR -25385C > T) as well as determination of the FXR downstream
product, fibroblast growth factor (FGF) 19 was performed. Primary outcomes included risk and time
to first CD-related surgery. The effect of estrogen on wild type and variant FXR activity was assessed
in HepG2 cells. The FXR-1GT genotype was associated with the risk of (odds ratio, OR = 3.34, 95%
CI = 1.58–7.05, p = 0.002) and earlier progression to surgery (hazard ratio, HR = 3.00, 95% CI = 1.86–
4.83, p < 0.0001) in CD. Female carriers of the FXR-1GT genotype had the greatest risk of surgery
(OR = 14.87 95% CI = 4.22–52.38, p < 0.0001) and early progression to surgery (HR = 6.28, 95% CI = 3.62–
10.90, p < 0.0001). Women carriers of FXR-1GT polymorphism had a three-fold lower FGF19 plasma
concentration versus women with FXR-1GG genotype (p < 0.0001). In HepG2 cells cotransfected with
estrogen receptor (ER) and FXR, presence of estradiol further attenuated variant FXR activity. MDR1
and PXR genotypes were not associated with surgical risk. Unlike MDR1 and PXR, FXR-1GT genetic
variation is associated with earlier and more frequent surgery in women with CD. This may be through
ER-mediated attenuation of FXR activation.
Crohn’s disease (CD) is an immune-mediated inflammatory bowel disease defined by remitting and relapsing
episodes of intestinal i nflammation1. CD pathogenesis is complex. Dysregulation of the host immune response
in the setting of specific environmental and genetic factors are hypothesized to serve as disease p
 recursors1,2. A
key component of this inappropriate immune response is the disruption of the mucus layer, the loss of epithelial
tight junctions and an increased intestinal permeability and thereby an increase in the intestinal immune system’s
exposure to bacteria, resulting in an immune response via its innate and adaptive arms1. Furthermore, there is
a shift in production from anti-inflammatory proteins to pro-inflammatory cytokines through the activation of
nuclear transcription factors such as nuclear factor κB (NFκB)3. Early in its course, CD is remitting and relapsing, with periods of activity punctuated by debilitating symptoms of abdominal pain, diarrhea, and weight loss,
accompanied by biochemical and endoscopic findings of inflammation. As the disease progresses over time,
permanent damage to the intestinal structure may result, leading to an irreversible impairment of intestinal
function, significant morbidity and long-term disability. Disease severity is marked by the need for and time to
surgery, failure of multiple medical therapies, need for hospitalization and the presence of complications such
as fistulae or s trictures4.
Many studies have attempted to link genetic variation in key genes associated with inflammation, xenobiotic metabolism and transport as well as gene regulators of such pathways to CD susceptibility. Several single
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nucleotide variations (SNVs) in the multidrug resistance-1 (MDR1) gene, the pregnane X receptor (PXR, also
NR1I2) gene, and to a lesser extent, the farnesoid X receptor (FXR, also NR1H4) gene have been evaluated, and
some linked to IBD susceptibility with varying degrees of s uccess5–13; however, none have emerged as a clinically
meaningful marker of IBD presence, drug response or disease severity.
There is now an increasing appreciation of the bile acid-sensing nuclear receptor, FXR, as the master regulator
of bile acid homeostasis and transport pathways, intestinal inflammation, intestinal permeability and response to
bacterial overgrowth3,14,15. Animal models confirm that in the absence of FXR activation, there is an expansion
of the bile acid pool and a more severe presentation of chemically-induced colitis, including increased intestinal cellular infiltrate, collagen deposition and expression of inflammatory g enes3,14. FXR activation modulates
fibroblast growth factor (FGF) 19 expression, and plasma FGF19 concentrations have been used as a surrogate
marker of FXR activity16,17. Moreover, FXR activation in these same models improves intestinal permeability
and attenuates the production of pro-inflammatory cytokines such as IL-1β and TNFα via the NFκB p
 athway3,14.
Our group was the first to identify and demonstrate that FXR-1G > T, a SNV adjacent to the ATG start codon
located within the Kozak consensus motif of the FXR gene, is linked to reduced transactivation of FXR gene
targets18. Since the Kozak consensus motif ensures ribosomal binding to mRNA transcripts and efficient protein
translation, genetic variation in this conserved sequence is associated with decreased protein translation19. Previously, Van Mil et al.20 demonstrated that the FXR1-1G > T is associated with reduced FXR protein expression as
well as decreased activation of its down-stream targets, citing translational inefficiency as the underlying cause.
Accordingly, FXR-1G > T may have important functional consequences. Interestingly, complete FXR deficiency,
while rare, does exist in the human population, and has been shown to result in progressive familial intrahepatic
cholestasis (PFIC), associated with coagulopathy, jaundice and a rapid progression to liver f ailure21,22. Such data
suggest major loss of function mutations in FXR as contributors to CD are unlikely; however, partial loss of
function or expression of FXR may contribute to CD progression or severity. To date, the role of the FXR-1G > T
SNV has only been evaluated in a CD population in a very limited capacity11.
Accordingly, we hypothesized that changes in the intestinal barrier as a result of reduced FXR expression
among those who harbor the FXR-1T allele are more likely to exhibit a severe CD phenotype compared to G
(reference) allele carriers, and thereby experience a more rapid progression to surgery. Alterations in FXR activity
may in part be secondary to genetic variation in the FXR gene. The aim of this study was to evaluate the utility of
FXR-1G > T as a genomic biomarker of severity in CD. Herein, we demonstrate the clinical impact of the FXR1G > T SNV in a large CD population, and provide insights regarding underlying mechanisms.

Methods

Study design and participants. This study was a retrospective, single centre, cohort study carried out in

542 patients with CD, who were seen as part of the Personalized Medicine Program at Western University, London, Canada between March 2013 and November 2018 (Flow chart in Supplementary Figure 1). Additionally, all
subjects were screened for MDR1 3435C > T and PXR -25385C > T. Subjects who underwent a CD-related intestinal resection were also assessed for FGF19 plasma concentration. All eligible subjects were more than 18 years
of age, and had a histopathological diagnosis of CD. Patients were excluded from the primary analysis if information pertaining to their medical history was unavailable or unknown or if they had a diagnosis of ulcerative
colitis, UC. Other exclusion criteria included a known history of liver or biliary disease, use of cholestyramine
or antibiotics within 4 weeks of blood sampling. Subjects excluded from the primary analysis based on a diagnosis of UC were evaluated for surgical risk and progression to surgery based on FXR-1G > T genotype and are
described in the Supplemental Section.

Demographic and covariate data abstraction. Data collected on subjects from both cohorts included

age, sex, weight, smoking history, medical history, duration of disease as well as CD medication exposures
(defined as the receipt of, at a minimum, one dose of a CD-related drug as reported by the patient to their treating gastroenterologist) and responses (adverse drug reactions (ADRs), induction of remission, resistance or loss
of response). Data relevant to their CD diagnosis was also collected including disease phenotype, disease activity
(based on the clinical scoring index, Harvey-Bradshaw Index, HBI) at the time of blood collection, hospitalizations, and history of and time to surgical resection. This information was collected from patient hospital records
between the date of diagnosis and the study end period (June 1, 2019).

Genotypic analysis. Each subject provided a 5 mL venous blood sample used to extract DNA by a standard
protocol (MagNA Pure Compact System, Pleasanton, California). Allelic discrimination using TaqMan assays
and a 7500 RT-PCR System (Applied Biosystems, Carlsbad, CA) was performed to determine the following genotypes in CD subjects with available DNA (n = 542): FXR -1G > T (rs56163822; Taqman assay ID C_25598386_10,
Thermofisher), MDR1 3435C > T (rs1045642; Taqman assay ID C_7586657_20, Applied Biosystems), and PXR
(NR1I2) -25385C > T (rs3814055; Taqman assay ID C_27504984_30, Thermofisher). Genotyping experiments
included three positive controls with previously established genotypes and one negative control. For quality
control, 5% of samples were genotyped in duplicate. Congruency was seen amongst all duplicated genotypes.
Fibroblast growth factor 19 quantification. Blood samples were drawn from study subjects and
plasma was extracted by centrifugation. All subjects provided blood samples post-operatively. A commercial
enzyme-linked immunosorbent assay (ELISA) kit (FGF19 Quantikine ELISA kit, R&D Systems, Minneapolis,
MN, US) was used for the colorimetric detection and estimation of FGF19 plasma concentrations following the
manufacturer’s instructions for subjects with available plasma samples who underwent surgical intervention
(n = 176). All plasma aliquots as well as the standard curve (0–1000 pg/mL) were assayed in duplicate.
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Study objectives and outcomes. The objective of this study was to test the hypothesis that FXR-1G > T is

a predictor of disease severity in CD. The primary endpoints were the risk of surgery and time to surgery in the
FXR-1GG versus -1GT CD populations. Secondary outcomes included other indicators of severity such as number of hospitalizations and number of failed medications, all standardized to per-year of CD diagnosis. Other
endpoints included potential differences in plasma concentration of FGF19 in these two genotypic populations.
Moreover, we evaluated the rate of surgery, time to surgery, hospitalizations and number of failed medications
amongst wild type and variant carriers of the MDR1 3435C > T (rs1045642) and PXR -25385C > T (rs3814055).

Cell‑based studies. Plasmid constructs. Human (h) FXR-pEF6, hFXR-1GT-pEF6, pRNL-CMV and
BSEP-pGL3 were generously provided by Dr. Rommel G. Tirona. Plasmids containing the coding sequence of
the estrogen receptor α and β (ERα-pCMV6-XL4 and ERβ-pCMV6-XL4) were purchased from Origene Technologies (Rockville, MD, USA) and subcloned into the pEF6 expression vector using a PCR cloning method23.
Specifically, the ERα and ERβ open reading frames were respectively amplified by PCR (primers described in
Supplementary Table 1), subcloned into pEF6, and their presence confirmed by Sanger sequencing.
Transient transfection. Human hepatocarcinoma (HepG2) cells, obtained from American Type Culture Collection (Manassas, VA), were grown in Dulbecco’s Modified Eagle Medium (VWR, Radnor, Pennsylvania) supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin.
Cells were seeded in 12-well plates to 90% confluency in 2 days, and subsequently transfected using lipofectin
(3 μL/μg of DNA, Lipofectamine 3000, Invitrogen, Carlsbad CA) with one of the following: 250 ng of hFXRpEF6, ERα-pEF6, ERβ-pEF6, and BSEP-pGL3; or hFXR-1GT-pEF6, Erα-pEF6, Erβ-pEF6, and BSEP-pGL3; or
blank expression vector.
Gene expression. To test the integrity of the subcloned ERα and ERβ after transfection, gene expression was
determined after treatment with estradiol (E2) in HepG2 cells. Specifically, cells were transiently transfected
using 1000 ng ERα-pEF6, ERβ-pEF6, or empty vector. Prior to RNA extraction, cells were treated for 24 h with
10 nM E2, 100 nM E2, 1 μM E2, or 0.1% DMSO control. Total RNA was extracted with Trizol reagent as per
the manufacturer’s instructions (Invitrogen). After RNA quantification and confirmation of integrity (DeNovix
spectrophotometer) complementary DNA (cDNA) was synthesized using MultiScribe Reverse Transcriptase
(RT) and random priming (Applied Biosystems, Foster City, CA). Expression of ERα and ERβ as well as p53
expression was measured by quantitative real time RTPCR (qPCR) using SYBR green detection (FroggaBio,
Toronto, ON, Canada) with the ABI 7500 sequence detection system (Applied Biosystems, Foster City, CA).
Transcript levels were normalized to 18s rRNA (TaqMan assay ID Hs99999901_s1, Applied Biosystems), and
relative expression determined using the 2−ΔΔCT method24. Data are presented as fold-change. Primer sequences
are detailed in Supplementary Table 1.
Luciferase activation assay. HepG2 cells were transfected with ER as described above with the addition of
10 ng of pRNL-CMV per well. After 16 h, cells were washed with Optimem (Gibco, Gaithersburg, MD) and
incubated in one of the following: 0.1% DMSO; 10 nM chenodeoxycholic acid (CDCA); 10 μM CDCA and
10 nM β-estradiol (E2); 10 μM CDCA and 100 nM E2; 10 μM CDCA and 1 μM E2. Cell viability, in presence of
increasing concentrations of E2 for 24 h (10 nM, 100 nM, 1 μM), was assessed by a luminescent assay (CellTitreGlo, Promega, Madison WI) prior to the above incubations. Luciferase activities were measured using the Dual
Luciferase Reporter Assay Kit (Promega, Madison WI) as per the manufacturer’s instructions, and luminescent
signal determined (Glomax 20/20 Luminometer, Promega, Madison Wisconsin, USA). Data were normalized
by dividing the firefly luciferase activity by the Renilla luciferase activity (F/R ratio). Data are shown as the foldchange in luciferase activity by dividing the F/R ratio by the control.

Statistical analysis. Given a reported frequency of 8% of the FXR -1G > T SNV amongst all ethnicities

(ExAC database, 1000Genomes database), a minimum of 21 subjects in the FXR-1G > T variant group (GT) and
347 in the FXR-1G > T wild type group (GG) would be needed to detect a 30% difference in the incidence of
surgery to achieve a power of 80% with a 2-sided p value threshold of 0.05.
Statistical analysis was performed using GraphPad Prism version 5, R version 3.5.3, and SPSS version 17.0
statistical software. Allele frequency distribution for the FXR -1G > T, MDR1 3435C > T and PXR -25,385 genotypes were tested for Hardy–Weinberg equilibrium using a χ2 goodness-of-fit test. A Cox proportional-hazards
regression model with adjusting covariates was used to assess the influence of FXR-1T, MDR1 3435T and PXR
-25385T variant carrier status on the time to first surgical resection for the total population, males and females
and hazard ratios (HR) were expressed with 95% confidence intervals (CI). Risk of surgery associated with FXR1GT, MDR1 3435T and PXR -25385T variant carrier status was evaluated using a logistic model with adjustment
and are expressed as odds ratios (OR) with 95%CI. Covariates that were considered included the following: age,
weight, exposure to combined therapy with an immunosuppressant and biologic, any biologic, methotrexate,
glucocorticoid or thiopurine exposure, biologic f ailure25 (defined as development of an ADR requiring cessation of the biologic; primary non-response: a lack of improvement in clinical symptoms with induction therapy
as defined by their treating physician; or loss of response: a recurrence in disease activity during maintenance
therapy despite an adequate response to induction dosing as defined by the treating physician), any drug failure,
hospitalizations, smoking history, duration of disease, and pre-operative biologic exposure. A final model was
constructed for the total population as well as stratified by sex, adjusting for FXR-1G > T genotype, age, weight
and other, aforementioned covariates.
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Characteristics

Subjects with CD (n = 542)

Age, years (mean, range)

41.63 (18–85)

Female sex (%)

321 (59.2)

Weight, kg (mean ± SD)

76.97 ± 19.26

Disease location
Ileal

199 (36.7)

Colonic

99 (18.3)

Ileo-colonic

241 (44.7)

Median HBI (IQR)

4.5 (2–8)

Median disease duration, years (IQR)

4.58 (1.50–13.58)

Smoking history (%)

159 (29.3)

Prescription of a biologic agent (%)

250 (46.1)

Anti-TNF (%)

212 (39.1)

Anti-integrin (%)

20 (3.7)

Anti-IL12/23 (%)

22 (4.1)

Combination therapy (%)

184 (33.9)

Glucorticoid exposure (%)

396 (73.1)

Immunomodulator exposure
MTX (%)

128 (23.6)

Thiopurine (%)

313 (57.7)

Number of drugs failed (mean ± SD)

1.08 ± 1.27

Number of biologics failed (mean ± SD)

0.33 ± 0.72

Surgery (%)

183 (33.8)

Mean number of surgeries (mean ± SD)

0.57 ± 1.09

Hospitalizations (mean ± std)

1.10 ± 2.05

FXR -1GT carrier status (%)

31 (5.7)

FXR-1GG carrier status (%)

511 (94.3)

MDR1 3435CC carrier status (%)

148 (27.3)

MDR1 3435CT/TT carrier status (%)

394 (72.7)

PXR -25385CC carrier status (%)

193 (35.6)

PXR -25385CT/CC carrier status (%)

349 (64.4)

Table 1.  Baseline characteristics. kg kilograms, SD standard deviation; CD Crohn’s disease; HBI HarveyBradshaw Index, IQR interquartile range, TNF tumor necrosis factor, IL interleukin; MTX methotrexate, FXR
farnesoid X receptor, MDR multi-drug resistance, PXR pregnane X receptor.

To test the hypothesis of an association between the FXR-1G > T SNV and a decrease in the downstream FXR
target, FGF19, a Welch’s t-test was used to compare FGF-19 plasma concentrations between genotype groups
(FXR -1G > T variant carriers vs wild-type) within the surgical cohort (n = 176). A p value < 0.05 was considered
significant. A multiple linear regression analysis was used to further evaluate the relationship between FXR-1T
carrier status, other covariates and the inter-individual variation in FGF-19 plasma concentrations (natural logtransformed) in participants who underwent a surgical intervention. The analysis was performed for the total
population as well as stratified by sex. Other covariates assessed included the following: age, weight, disease
activity, disease location and history of small bowel resection.
All in vitro experiments were carried out in duplicate and repeated 3 times. Statistical differences between
groups were evaluated using a Student’s t test. A one-way ANOVA with a post hoc Tukey’s Multiple Comparison
Test was used to compare luciferase activities within groups. A p value < 0.05 was considered significant.

Ethical considerations. The study protocol was approved by the Western University Health Sciences
Research Ethics Board. All study subjects provided written informed consent. All methods were performed in
accordance with the relevant guidelines and regulations of the Tri-Council Policy Statement.

Results

Study population. Subject selection for all participants, as well as baseline characteristics of CD patients,

are presented in Supplementary Figure 1 and Table 1. 1,005 patients referred to the London Health Sciences
Centre Personalized Medicine Clinic for disease-specific pharmacogenomic testing were screened for inclusion.
Individuals without a confirmed diagnosis of IBD or individuals with missing data or those meeting the exclusion criteria were not included in the final analysis (n = 225). Individuals with a diagnosis of UC were excluded
from the primary analysis (n = 201); however, they did undergo genotypic analysis to assess FXR-1G > T carrier
status. Their demographic data is summarized in Supplementary Table 2. 542 patients with CD were included
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Cohort (n = 542)
Risk of event

Odds ratio

95% CI

p value

Total population
Unadjusted

3.34

1.58–7.05

0.002

Adjusted

2.77

1.012–7.58

0.047

Female
Unadjusted

14.87

4.22–52.38

< 0.0001

Adjusted

21.33

3.78–120.3

0.001

Male
Unadjusted

0.49

0.13–1.86

0.29

Adjusted

0.584

0.12–2.82

0.50

Table 2.  Risk of Surgical Intervention according to FXR-1G > T genotype. Odds ratios were adjusted for the
following covariates: age, weight, exposure to combination therapy with a biologic and immunosuppressant
agent, any biologic, methotrexate, glucocorticoid or thiopurine exposure, biologic failure, any drug failure,
hospitalization, smoking history, duration of disease, and pre-operative biologic exposure. CI confidence
interval, FXR farnesoid X receptor.

in the final analyses of which 176 participants had undergone an intra-abdominal surgical intervention for their
CD. The rate of surgery increased with duration of diagnosis (1-year, 10.15%; 5-year, 21.77%; and 10 years after
diagnosis, 28.04%). The most common indication for surgery was stricturing disease (FXR-1GG, n = 78; FXR1GT, n = 10) followed by fistulizing disease (FXR-1GG, n = 45; FXR-1GT, n = 5). Surgical interventions included
small bowel or ileocolic resections with primary anastomosis and total colectomies with formation of an ileostomy. Supplementary Table 3 summarizes the demographic data for all CD subjects stratified by surgical status
and FXR-1G > T genotype.

FXR‑1G > T predicts surgery risk and an earlier progression to surgery in women with
CD. Among all subjects in the CD cohort, FXR -1G > T minor allele (-1T) frequency was 2.9%, while allele

frequency was in Hardy–Weinberg equilibrium. The incidence of surgery was higher in FXR-1T variant carriers
compared to wild type individuals (61.3% vs 30.7%). There was a strong association between the presence of the
variant T allele and surgical intervention (unadjusted OR = 3.34, 95% CI = 1.58–7.05, p = 0.002). After adjustment for baseline covariates and treatment regimens, the FXR-1GT genotype remained a significant predictor
of surgical risk (Table 2).
FXR-1T variant carriers were more likely to go on to a surgical intervention earlier in their disease course compared to wild type individuals (6.08 years ± 7.16 vs 2.69 years ± 2.26; unadjusted HR = 3.00, 95% CI = 1.86–4.83,
p < 0.0001) (Fig. 1a). Similarly, FXR-1GT remained an independent predictor of rapid progression to surgery
with adjustment for baseline covariates and drug exposures and responses (Table 3).
Interestingly, when data were stratified based on sex, the association between variant T allele carrier status and
risk of surgical intervention (Table 2) and an earlier progression to surgical intervention (Fig. 1b) was strongest
in women, even when adjusted for baseline covariates with an OR of 21.3 (p = 0.001, Table 2) and HR of 4.33
(p < 0.0001, Table 3). Of the FXR-1GT carriers going on to surgery, 84.2% were women compared to only 46.5%
in FXR-1GG carriers. Conversely in men, FXR-1G > T genotype was not significantly associated with risk or time
to surgery (Fig. 1C, Tables 2, 3).
Other indicators of severity evaluated included the number of drugs related to IBD failed, number of surgeries, and hospitalizations. There was no difference between FXR-1G > T genotypes in any of these parameters of
severity, even when adjusting for weight, age, sex and disease duration (data not shown).
In patients with UC (described in Supplementary Table 2), FXR-1G > T was not a predictor of surgical risk
or risk of early surgery (Supplementary Figure 2). No subjects with a FXR-1GT genotype underwent a surgery
related to their UC.

PXR and MDR1 genotypes are not associated with a severe CD phenotype. Additionally, sub-

jects were assessed for the SNVs, MDR1 3435C > T and PXR -25385C > T. Minor allele frequencies were 53.7%
and 40.2%, respectively, in the population. Overall, there was no significant association between either SNV
and risk of or time to surgical intervention (Supplementary Figures 3, 4). Furthermore, there was no significant
association between either SNV or other indicators of CD severity (number of drugs failed, number of surgeries,
hospitalizations).

FXR‑1G > T is associated with lower FGF19 plasma concentrations in women. Another objec-

tive of this study was to evaluate FGF19 plasma concentrations. Compared to FXR-1GG wild type carriers,
FGF19 plasma concentrations were lower in FXR -1GT variant carriers (Mean ± standard deviation, SD: -1GG
carriers = 0.38 ± 0.47 pg/L; -1GT carriers = 0.17 ± 0.18 pg/L, p = 0.0008) (Fig. 2a), even after adjustment for the
baseline covariates age, sex, weight, disease activity and intestinal resection (p < 0.0001, Supplementary Table 4).
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Figure 1.  Time to first surgery following the diagnosis of CD stratified by FXR-1G > T genotype expressed
as wild type (GG) or variant (GT) for the total population, n = 542 (A); for women, n = 321 (B); and for men,
n = 220 (C). ‘***’ represents a p value < 0.0001. CD Crohn’s disease, FXR farnesoid X receptor.

Cohort (n = 542)
Hazard ratio

95% CI

p value

Unadjusted

3.00

1.86–4.83

< 0.0001

Adjusted

2.67

1.59–4.47

< 0.0001

Unadjusted

6.28

3.62–10.90

< 0.0001

Adjusted

4.33

2.23–8.41

< 0.0001

Unadjusted

0.76

0.24–2.41

0.64

Adjusted

1.37

0.41–4.62

0.61

Risk of event
Total population

Female

Male

Table 3.  Hazard ratios of surgical risk for FXR-1GT versus FXR-1GG Genotypes. Hazard ratios were
adjusted for the following covariates: age, weight, exposure to combination therapy with a biologic and
immunosuppressant agent, any biologic, methotrexate, glucocorticoid or thiopurine exposure, biologic failure,
any drug failure, hospitalization, smoking history, duration of disease, and pre-operative biologic exposure. CI
confidence interval, FXR farnesoid X receptor.
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Figure 2.  The mean FGF-19 plasma concentrations stratified by FXR-1G > T genotype, GG or GT for the total
population (A), for women (B) and for men (C). Error bars represent the standard deviation. ’***’ represents a p
value < 0.0001. Fibroblast growth factor 19, FGF-19; farnesoid X receptor, FXR.
Interestingly, when stratified by sex, women with an FXR-1GT genotype had a near three-fold lower FGF-19
plasma concentration (GG = 0.43 ± 0.0.54 pg/L; GT = 0.16 ± 0.18 pg/L, p = 0.001, Fig. 2b) even with adjustment
for the aforementioned covariates (Supplementary Table 5). There was no difference in the male population
(Supplementary Table 6).

ER‑FXR interplay. To better elucidate a potential molecular basis for the observed effect of FXR-1G > T
genotype on CD prognosis (more frequent and earlier surgery) in female CD patients, we explored a connection between the estrogen receptor-mediated pathway and genetic variation in FXR. First, ERα and β expression and function were assessed in our cell-based model after transfection with human ERα and β (Figs. 3, 4).
Increased relative mRNA expression of ERα, ERβ and the shared target p53 were observed with increasing
concentrations of estradiol (E2) (Fig. 3). To further assess the effect of estrogen on FXR-mediated transcriptional activation of the prototypical FXR target gene ABCB11 (bile-salt export pump, BSEP), HepG2 cells were
co-transfected with human ERα and β, FXR wild type (FXR WT-ERα-ERβ) or variant (FXR-1GT-ERα-ERβ),
and a BSEP promoter-luciferase reporter gene. The BSEP-luciferase reporter was robustly activated by FXR WT
in the presence of CDCA (10 μM) while for FXR-1GT, reporter luciferase activity was only 45% of wild type
FXR (Fig. 4, p < 0.0001). Moreover, CDCA-induced BSEP-luciferase reporter activity decreased with increasing
concentrations of E2 (Fig. 4, p < 0.0001), with the greatest decrease seen in variant FXR-expressing cells. No significant differences in cell viability were observed in E2 treated cells (10 nM, 100 nM, 1 μM) compared to control
as confirmed by a luminescent assay (CellTitre-Glo, Promega, Madison WI, data not shown).

Discussion

There is an increasing appreciation of the role of nuclear receptors as determinants of cellular homeostasis as well
as in disease pathogenesis, modulation, and therapeutic t argets26. To date, the clinical relevance of genetic variation in nuclear receptors on disease conditions such as inflammatory bowel disease has not been convincingly
demonstrated. This may in part be related to the multifactorial effect of diet, environment, gut microbiome, as
well as host genetics to susceptibility of IBD and treatment outcomes.
Two previous studies have evaluated polymorphisms in FXR and in the setting of IBD10,11. Nijmeijer et al.
did not find an association between FXR-1T variant carrier status and IBD disease presence, location or disease
type among 2,355 IBD patients. Similarly, Attinkara et al. failed to show an association between FXR-1T variant
carrier status and IBD susceptibility in a cohort of 1,138 individuals, half of whom had a CD diagnosis. However,
in those studies, no assessment was performed to evaluate the link between FXR-1G > T and disease severity,
potential molecular mechanism or sex related differences in disease severity.
In this study, we demonstrate women with CD carrying the FXR-1GT genotype are at a much higher risk for
progressing on to surgery (adjusted OR = 21.33, 95% CI = 3.78–120.3, p = 0.001) compared to men or women
with the FXR-1GG genotype. Sex-specific differences in CD have only been explored to a limited extent. Most
recently, Shah et al. and Severs et al. showed sex-specific differences in the incidence of IBD and across several
clinical variables associated with disease p
 henotypes27–29. However, there is a paucity of data on how sex differences impact CD diagnosis and disease management27–29. This is in contrast to the depth of our understanding
of sex-related differences in other chronic diseases such as coronary artery disease, rheumatologic autoimmune
diseases, and renal disease30. Even in conditions where sex-related differences are known to exist, disparity in
disease management is often seen. For example, despite better outcomes in females, women with congestive heart
failure receive fewer guideline-based treatments and transplantations compared to men31. Similarly, despite a
greater risk of stroke, women are less likely to be anticoagulated in the setting of atrial fibrillation compared to
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Figure 3.  Effect of estradiol on ER-α (ESR1) and ER-β (ESR2) gene expression in addition to the shared
ER-target gene p53. HepG2 cells were transiently transfected with ER-α (ESR1), ER-β (ESR2) or vector control
(pEF6). ESR1 (A), ESR2 (B) and p53 (C, D) mRNA expression was determined by real-time qPCR analysis.
ER Estrogen receptor, ESR estrogen receptor gene, Hep hepatoma, mRNA messenger ribonucleic acid, PCR
polymerase chain reaction.

men31. Such differences and potential disparities have not yet been addressed adequately in CD. There are data
to support a slightly higher incidence of CD in women across several populations32–34. Oral contraceptive pill
(OCP) use has been linked to the onset of CD in a large prospective cohort study of American women as well as
to the risk of CD-related surgery in a Swedish r egistry35,36. These findings allude to the importance of a femalespecific factor to the susceptibility and severity of CD.
Interestingly, E2, a major female sex hormone and the dominant form of estrogen present during a woman’s
reproductive years and commonly used in OCP, has been shown to inhibit FXR activity via the ERα in vivo and
in vitro37,38. However, the molecular mechanism that govern a potential relationship between, for example, OCP
use and CD susceptibility, have not been elucidated35,36. Interestingly, Goodman et al.39 using a murine model of
colitis, showed that ER-α loss-of-function resulted in protection from chemically-induced colitis in female mice,
directly linking E2-signaling to pathways of IBD. Our findings suggests a plausible molecular mechanism. Our
experiments demonstrate that estrogen-mediated ER activation attenuates bile acid-mediated FXR activation,
and that the inhibitory effect was more profound in the presence of the variant FXR.
We did not observe an association of MDR1 3435C > T and PXR -25385C > T genotypes with CD severity in
our population. To date, there has been a lack of consensus regarding a potential link between CD susceptibility
and genetic variation in MDR1 and PXR. Brinar et al. and Juyal et al. both indicated a link between MDR1 genetic
variation and IBD, while a larger meta-analysis of existing studies refuted the finding5,12,40. Similarly, Dring et al.6
concluded that PXR -25385C > T was a significant predictor of IBD susceptibility; however, more recent and
larger genomic association studies have failed to confirm these original findings7,9. Our study confirms a lack of
association between functional polymorphisms in either of these genes and CD severity.
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Figure 4.  Effect of estradiol on the FXR-mediated activation of BSEP-pGL3 basic reporter activity in HepG2
cells co-transfected with ERα-pEF6, ERβ-pEF6 and one of hFXR-pEF6 or hFXR-1GT-pEF6 or a vector
control. Cells were incubated with CDCA alone or with CDCA in combination with estradiol in increasing
concentrations (10 nM, 100 nM, 1 µM) for 24 h. Data are normalized to renilla luciferase activity and presented
as the fold-change relative to the vector control as mean ± SEM. ‘***’ represents p values < 0.0001, ‘**’ represents
p values < 0.001 and ‘*’ represents p values < 0.01. Three independent experiments were performed for each
model. CD Crohn’s disease, FXR farnesoid X receptor, BSEP bile salt export pump, pGL3 luciferase, Hep
hepatocarcinoma, ER estrogen receptor; pEF6 expression vector, h human, SEM standard error of the mean,
CDCA chenodeoxycholic acid.
Interestingly, the FXR-1GT genotype was not associated with risk of surgery or earlier progression to surgery
in a cohort of individuals with UC. This may be related to a relatively small cohort size (201) in addition to the
low incidence of surgery in this group (18/201). Mechanistically, the study of differences in FXR activation in
IBD has commonly identified differences in CD and not UC11,15,41. Conversely, one might expect the association
between FXR-1GT and surgical risk to extend to a UC population given there are many shared inflammatory
pathways in CD and UC that are regulated by FXR and abnormalities in epithelial barrier function are documented in both conditions. Further study in a larger cohort may be warranted and other endpoints related to
barrier function (disease flares) should be considered.
Importantly, we demonstrate differences in FGF19 plasma concentration, a FXR downstream product,
between carriers of the FXR-1GT genotype versus -1GG genotype (Fig. 2). This difference was most pronounced
in women, with a near three-fold higher FGF19 plasma concentration in carriers of the wildtype allele compared
to carriers of the variant FXR-1T allele. We have previously shown in vitro and in vivo that the FXR-1G > T SNV
is associated with reduced activation of downstream products18. Similarly, data by Van Mil et al.20 demonstrated
a concomitant decrease in FXR protein and several of its down-stream gene targets.
A limitation of our study may include that FGF19 quantification was carried out in individuals with small
bowel disease who underwent a small bowel resection of varying, non-quantifiable lengths. This may have
impacted FGF19 plasma concentrations and thus confounded our findings. Moreover, this is a largely Caucasian
study, and as such may not be generalizable to other populations. Furthermore, it is a retrospective and uncontrolled cohort study; thus, it may be affected by selection bias and unknown confounding factors. Lastly, there
is no replication cohort for the clinical data set. Additional studies are needed to further assess the relationship
between FXR-1G > T and CD severity.

Conclusions

This study outlines important new findings of particular relevance to women with CD. Screening female CD
patients for FXR-1T variant carrier status may be useful for identifying female patients at risk for poor outcomes.
Female carriers of the variant allele may benefit from earlier, more aggressive medical management.
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